News
Market and company headlines
ZBHAll
Loading
06:00Oct 221 Story
08:00Oct 211 Story
05:00Oct 141 Story
03:00-08:00Oct 132 Stories
ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced a multi-year extension of its Limited Exclusive Distribution and Supply Agreement following a successful partnership during the initial term of the agreement.
Zimmer Biomet Expands Its Distribution, Supply Deal With THINK Surgical To Continue Distribution Of THINK's Wireless TMINI Miniature Robotic System
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced a multi-year extension of its
08:00-19:00Oct 122 Stories
Surgical Equipment & Consumables - Diversified Stocks Q2 Results: Benchmarking Zimmer Biomet (NYSE:ZBH)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including Zimmer Biomet (NYSE:ZBH) and its peers.
Should Value Investors Buy Zimmer Biomet (ZBH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
05:00Oct 71 Story
07:00Oct 61 Story
15:00Sep 291 Story
12:00Sep 281 Story
12:00-21:00Sep 252 Stories
Zimmer Biomet (ZBH): Buy, Sell, or Hold Post Q2 Earnings?
Zimmer Biomet currently trades at $91.50 per share and has shown little upside over the past six months, posting a middling return of 4.4%. The stock also fell short of the S&P 500’s 16.9% gain during that period.
Zimmer Biomet Holdings (ZBH) Pushes Cost Reset Plans, Is It Still 17% Below Fair Value?
Zimmer Biomet Holdings: recent performance and context Zimmer Biomet Holdings (ZBH) has drawn investor attention after a stretch of weaker share performance, with the stock down 1.3% over the past day and 10.5% over the past month. At a share price of US$89.69, Zimmer Biomet Holdings has seen momentum fade recently, with the 30-day share price return down 10.5% and the 1-year total shareholder return declining 6.5%. This points to cooler sentiment following earlier periods of...
14:00Sep 241 Story
15:00-18:00Sep 232 Stories
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.
These S&P500 stocks are moving in today's session
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
11:00-13:00Sep 212 Stories
Ambulatory Surgery Centers Are Becoming ISRG's New Growth Engine
Intuitive Surgical is expanding robotic surgery in ASCs with lower-cost XiR systems, opening access to new customers and outpatient procedures.
How Far Could ISRG Stock Bounce From Here?
Intuitive Surgical (ISRG) stock could climb 23.9% to the April high it last fell back from, and you would risk about 5% to find out. That looks like a surgical-robot leader on sale, but the price history disagrees. Over the last two years, none of its visits to this price range turned into a 20% gain before a 5% drop.
12:00Sep 161 Story
06:00-11:00Sep 142 Stories
How Zimmer Biomet’s New Americas and Robotics Leadership Structure At Zimmer Biomet Holdings (ZBH) Has Changed Its Investment Story
Zimmer Biomet Holdings, Inc. recently announced a major reshuffling of its leadership structure, effective October 1, 2026, promoting Gary Campbell to President, Americas; Brian Hatcher to President, Recon, S.E.T., CMFT, Neuro and Biosurgery; and Bradley Kessler to President, Americas – Robotics, Technology and Data, while Group President Kevin Thornal exited on September 30, 2026. This overhaul elevates long-tenured internal leaders with deep orthopedic, robotics and commercial experience,...
Zimmer proposes to cut 580 jobs in Switzerland
Reducing headcount at the Swiss site is part of an ongoing effort to simplify the company’s manufacturing footprint and supply chain.
05:00Aug 141 Story
13:00Aug 133 Stories
Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?
Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.
Is SYK Worth Buying as Growth Improves but Execution Risks Persist?
Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.
Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?
Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.
13:00-18:00Aug 122 Stories
The Paid-To-Hold Play On ISRG Stock: A 12% Annualized Income
Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.
Two Years Of Growth Barely Change What You Pay For Intuitive Surgical
Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.
